Incorrect password
evipedia.ai Suggest Edit

Cinnamon for Health & Longevity

Evidence Review created on 04/30/2026 using AI4L / Opus 4.7

Also known as: Cinnamomum verum, Cinnamomum zeylanicum, Ceylon Cinnamon, True Cinnamon, Cinnamomum cassia, Cassia Cinnamon, Cinnamomum burmannii, Indonesian Cinnamon, Korintje, Cinnamomum loureiroi, Saigon Cinnamon, Vietnamese Cinnamon

Motivation

Cinnamon is the dried inner bark of evergreen trees in the genus Cinnamomum, used for millennia as a culinary spice and as a traditional remedy across Ayurvedic, Chinese, and Greco-Roman medicine. Two commercial categories dominate the supply: Ceylon (the milder “true” cinnamon from Sri Lanka) and the cassia group, which accounts for over ninety percent of global production and carries a much higher content of coumarin.

Modern interest in cinnamon centers on its capacity to modulate blood sugar, blood lipids, and body weight. Dozens of randomized trials and multiple meta-analyses have examined whether daily supplementation in the gram range meaningfully shifts cardiometabolic biomarkers, and the resulting picture is informative but not uniform.

This review examines the current human evidence on cinnamon as a tool for health- and longevity-oriented adults: what controlled trials show for glucose, lipid, blood pressure, and body composition outcomes, the practical differences between cinnamon types, the dose ranges and durations linked to benefit, and where the coumarin profile narrows the choice of source.

Benefits - Risks - Protocol - Conclusion

This section curates accessible, high-level expert content that introduces cinnamon, its species variations, and the modern human evidence for its cardiometabolic effects.

  • Superfoods: Cinnamon - Mathena, 2024

    A consumer-facing Life Extension Magazine article that summarizes the human trial evidence for cinnamon at 3 g/day in T2DM (type 2 diabetes mellitus, the chronic adult-onset form characterized by insulin resistance and progressive beta-cell decline) and prediabetes — including HbA1c (hemoglobin A1c, a measure of average blood glucose over ~3 months) and fasting glucose changes — and outlines the practical 1.2 tsp/day dosing typically associated with metabolic benefit.

  • Cinnamon: Benefits, Forms, Dosing, and Side Effects - Stanfield, 2024

    A comprehensive evidence-summary by clinician Brad Stanfield covering the differences between Ceylon and cassia varieties, the strongest human trials for glycemic and lipid endpoints, the coumarin safety threshold, and a clear-eyed safety/interaction discussion — the most useful single-source clinician overview for separating cassia and Ceylon decisions.

  • Functional Medicine and Diabetes: How to Treat the Root Cause - Kresser, 2019

    Functional-medicine clinician Chris Kresser’s diabetes article situates cinnamon within a broader root-cause framework — citing the dose range of 120 mg to 6 g/day associated with reductions in fasting glucose, LDL-c (low-density lipoprotein cholesterol), and triglycerides — and frames the spice as a low-cost dietary tool rather than a primary therapy.

  • Cinnamon is metabolized to sodium benzoate, crosses the blood-brain barrier and protects against the progression of Parkinson’s disease - Patrick

    A FoundMyFitness research-curation page summarizing preclinical work on cinnamon’s principal hepatic metabolite (sodium benzoate), its CNS (central nervous system, the brain and spinal cord) bioavailability, and animal evidence for protection of dopaminergic neurons — useful context for the speculative neurological lane that motivates ongoing translational research.

  • Cinnamon, a promising prospect towards Alzheimer’s disease - Momtaz et al., 2018

    A widely cited Pharmacological Research narrative review surveying preclinical mechanisms by which cinnamaldehyde, cinnamic acid, and proanthocyanidins may interfere with tau (a neuronal protein whose abnormal aggregation is implicated in Alzheimer’s disease) aggregation, beta-amyloid accumulation, and neuroinflammation — the standard introductory citation for the neurodegeneration line of investigation.

Note: Peter Attia (peterattiamd.com) and Andrew Huberman (hubermanlab.com) do not have dedicated long-form content on cinnamon as a supplement; their platforms reference cinnamon only in passing within broader glucose-management and meal-timing discussions, which did not meet the high-level overview threshold for inclusion.

Grokipedia

Cinnamon

A comprehensive encyclopedic entry covering cinnamon’s botany (genus Cinnamomum, evergreen trees of South and Southeast Asia), the four principal commercial species, the dramatic difference in coumarin content between Ceylon (~0.004%) and cassia (~1%), traditional culinary and medicinal use across Asian cuisines and traditional Chinese medicine, and the modern but inconsistent evidence on blood-glucose modulation, including the practical implications of adulteration and overuse.

Examine

Cinnamon benefits, dosage, and side effects

The Examine.com entry summarizes cinnamon’s main supplement use cases — improvement of fasting glucose, lipid profile, blood pressure, and inflammation biomarkers in adults with metabolic disease — alongside the typical 1–6 g/day dose range, the limited but tolerable safety profile in short-duration trials, and the coumarin-driven concern that distinguishes cassia from Ceylon at the level of daily exposure.

ConsumerLab

Cinnamon Supplement and Spice Reviews & Top Picks

ConsumerLab’s member-facing review tested cinnamon supplements (Swanson, Trunature, GNC, NutriFlair) and ground spices (365/Whole Foods, Anthony’s, FGO, Frontier Co-Op, Kirkland, McCormick, Penzeys, Simply Organic, Trader Joe’s) for proanthocyanidin (PAC, the polymeric flavonoid believed to be cinnamon’s principal bioactive fraction) content, coumarin levels, and lead contamination. PAC content varied 10-fold between products (7.2 mg to 33 mg per daily serving), two supplements unexpectedly contained meaningful coumarin (suggesting cassia mislabeling as Ceylon), and one spice exceeded coumarin safety thresholds — making source verification a real-world quality issue.

Systematic Reviews

A real-time PubMed search for systematic reviews and meta-analyses of cinnamon returned a substantial cardiometabolic-focused evidence base; the most recent and comprehensive analyses are summarized below.

Mechanism of Action

Cinnamon’s bioactive footprint runs along several converging biochemical pathways, of which the glycemic and lipid effects are best characterized.

  • Cinnamaldehyde-driven insulin signaling. Cinnamaldehyde, the principal volatile compound, appears to enhance insulin receptor autophosphorylation and downstream phosphoinositide 3-kinase (PI3K) signaling, mimicking and potentiating insulin’s glucose-uptake action in skeletal muscle and adipose tissue. It also activates AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes glucose uptake and fatty-acid oxidation when cellular energy is low) in hepatocytes.

  • Alpha-glucosidase and alpha-amylase inhibition. Cinnamon extracts inhibit intestinal alpha-glucosidase and alpha-amylase enzymes (which cleave starches and disaccharides into absorbable monosaccharides), slowing postprandial carbohydrate absorption — a mechanism shared with the prescription drug acarbose.

  • Slowed gastric emptying. Controlled meal-tolerance testing suggests cinnamon delays gastric emptying, blunting the postprandial glucose excursion independent of any direct insulin-sensitizing effect.

  • Proanthocyanidin antioxidant capacity. Type-A proanthocyanidins (the polymeric flavonoids identified by ConsumerLab as the active fraction) exert potent free-radical scavenging, suppress NF-κB (nuclear factor kappa-B, a master regulator of inflammatory gene expression), and reduce oxidized LDL formation in vitro.

  • Lipid-modifying effects. Cinnamon downregulates HMG-CoA reductase (the enzyme statins inhibit) and upregulates LDL-receptor expression in animal models, plausibly contributing to the LDL-c, total-cholesterol, and triglyceride reductions observed in trials.

  • Neurological and other lanes. Cinnamaldehyde and its hepatic metabolite sodium benzoate cross the blood-brain barrier; preclinical work suggests interference with tau aggregation and beta-amyloid plaque formation, supporting the speculative neurodegeneration line of investigation. Cinnamon also has documented antimicrobial activity (cinnamaldehyde, eugenol) relevant to oral and gut microbiota effects.

The compound is a mixture rather than a pharmaceutical: cinnamaldehyde typically constitutes 60–75% of the volatile oil; coumarin, eugenol, cinnamic acid, polyphenols, and proanthocyanidins fill out the chemistry. Cinnamaldehyde is non-selective (a broad-acting modulator engaging insulin signaling, AMPK, and TRP channels (transient receptor potential channels, a family of cell-membrane ion channels involved in sensing temperature, pain, and chemical stimuli) rather than a single high-affinity receptor target), distributes widely across the gut, liver, skeletal muscle, adipose, and central nervous system (its hepatic metabolite sodium benzoate readily crosses the blood-brain barrier), and is metabolized primarily by hepatic conjugation (oxidation to cinnamic acid, glycine conjugation to hippuric acid; CYP-mediated pathways are secondary). Plasma half-lives of cinnamaldehyde and its primary metabolites (cinnamic acid, hippuric acid) are short (1–4 hours), with rapid first-pass conjugation in the liver — explaining why repeated daily dosing is required for sustained biomarker effects.

Historical Context & Evolution

Cinnamon enters the human record at least four thousand years ago: ancient Egyptian embalming texts mention it, Hebrew scripture lists it among the holy anointing oils, and Roman markets imported it via Arabian middlemen at prices comparable to gold. Its medicinal use spans Ayurvedic, traditional Chinese, and Greco-Roman systems, with indications ranging from digestive complaints and menstrual pain to respiratory infections and “cold” constitutional patterns.

Modern scientific interest in cinnamon as a glycemic agent is comparatively recent. A pivotal 2003 Pakistan-based RCT in T2DM by Khan and colleagues reported substantial reductions in fasting glucose and lipids at 1–6 g/day of cassia cinnamon — a result that triggered fifteen years of replication trials with mixed outcomes, owing to differences in cinnamon species, extract type, dose, baseline glycemic status, and concurrent diabetes therapy. Subsequent meta-analyses have largely vindicated the original glucose signal but with smaller effect sizes than the 2003 trial suggested, and with persistent heterogeneity.

Parallel toxicological work in Europe, particularly by Germany’s Federal Institute for Risk Assessment (BfR) in the late 2000s, brought coumarin into focus and effectively split cinnamon into two distinct safety categories. The European Food Safety Authority’s (EFSA) 0.1 mg/kg body weight tolerable daily intake for coumarin (5–7 mg for a typical adult) is exceeded by a single teaspoon of cassia cinnamon, recasting Ceylon cinnamon — long viewed as a connoisseur’s choice — as the safer option for daily therapeutic use. The current consensus does not characterize the field as settled: it continues to evolve as larger trials, dose-response analyses, and preclinical neurodegeneration work accumulate.

Expected Benefits

A dedicated search across PubMed, expert clinical sources, and primary-trial evidence informed the benefits below; the levels of evidence reflect the strength and consistency of the human RCT base.

High 🟩 🟩 🟩

Fasting Glucose Reduction in T2DM and Prediabetes

Cinnamon supplementation produces a consistent, statistically significant decrease in fasting blood glucose in adults with T2DM and prediabetes. The mechanism combines insulin-receptor sensitization, alpha-glucosidase inhibition, and slowed gastric emptying. Multiple meta-analyses converge on the effect: de Moura et al. (28 RCTs, n = 3,054) reported a weighted mean difference of −15.26 mg/dL versus control; Moridpour et al. (24 RCTs) and Zarezadeh et al. (umbrella, 11 meta-analyses) reported similar reductions. Encapsulated cinnamon at doses ≤2 g/day appears to produce the most consistent results, with effects emerging at 4–12 weeks.

Magnitude: −10 to −25 mg/dL fasting glucose at 1–3 g/day for 8–12 weeks in T2DM/prediabetes.

LDL Cholesterol and Triglyceride Reduction

In adults with metabolic disease, cinnamon supplementation reduces LDL-c, total cholesterol, and triglycerides while modestly raising HDL-c. The effect involves HMG-CoA reductase inhibition, LDL-receptor upregulation, and reduced postprandial lipemia. Jafari et al.’s 2025 GRADE-assessed (Grading of Recommendations Assessment, Development and Evaluation, a system for rating the quality of evidence in meta-analyses) meta-analysis (49 RCTs) reported SMDs (standardized mean difference, an effect-size metric for pooling across studies with different units) of −0.71 for LDL-c, −1.15 for total cholesterol, −0.91 for triglycerides, and +0.56 for HDL-c. Yu et al.’s dose-response analysis identified non-linear effects with maximal benefit at moderate doses.

Magnitude: LDL-c −7 to −15 mg/dL; triglycerides −20 to −30 mg/dL; HDL-c +1.5 mg/dL at 1–3 g/day for 8–12 weeks.

Medium 🟩 🟩

HbA1c Reduction in T2DM ⚠️ Conflicted

Cinnamon produces a small but statistically significant reduction in HbA1c — the integrated marker of glycemic control over the prior 8–12 weeks. The effect is more modest than the fasting-glucose change because HbA1c reflects mean glycemia over a longer window. de Moura et al. (28 RCTs) reported HbA1c −0.56%; Jafari et al. (49 RCTs) reported SMD −0.71; Moridpour et al. (24 RCTs) reported SMD −0.67. The Krittanawong et al. 2022 meta-analysis (American Journal of Medicine) found no HbA1c effect — the principal dissenting evidence — likely owing to inclusion of low-quality studies and a less metabolically diseased population.

Magnitude: −0.2% to −0.6% HbA1c at 1–3 g/day for 12 weeks.

Insulin Resistance Reduction (HOMA-IR)

In T2DM, prediabetes, and PCOS (polycystic ovary syndrome, a hormonal disorder characterized by irregular ovulation, androgen excess, and frequently insulin resistance) populations, cinnamon supplementation lowers HOMA-IR. The mechanism is the same insulin-receptor sensitization that underlies the fasting-glucose effect. Heshmati et al. (5 RCTs in PCOS) reported SMD −0.84; Zarezadeh et al. (umbrella) reported SMD −0.78 across T2DM and PCOS combined.

Magnitude: HOMA-IR reduction of approximately −0.6 to −1.0 units at 1.5–3 g/day for 8–12 weeks.

Body Composition Improvement

Cinnamon at doses ≥2 g/day for ≥12 weeks reduces body weight, BMI, waist circumference, and fat mass in adults with overweight or obesity. The mechanism likely combines AMPK activation, modest thermogenesis, and the postprandial glucose smoothing that may indirectly reduce hunger drive. Mousavi et al. (12 RCTs, n = 786) reported body weight −1.02 kg, BMI −0.51 kg/m², waist circumference −2.40 cm, and fat mass −1.02%. Keramati et al. (umbrella, 7 meta-analyses) reported similar pooled effects; effects are larger in adults <50 years and BMI ≥30 kg/m².

Magnitude: Body weight −1 to −2 kg; waist circumference −2 to −4 cm at 2–3 g/day for ≥12 weeks.

Low 🟩

Diastolic Blood Pressure Reduction

Cinnamon supplementation produces a small reduction in DBP, with less consistent effects on SBP. The mechanism may involve nitric-oxide-mediated vasodilation and modest insulin-sensitization-coupled vascular effects. Ghavami et al.’s 2021 meta-analysis (8 RCTs, n = 582) reported DBP −0.93 mmHg pooled; longer interventions (≥8 weeks) and higher doses (>1.5 g/day) produced the strongest signal. The Jafari et al. 2025 analysis reported larger SMDs (DBP −1.04, SBP −0.85).

Magnitude: DBP −1 to −2 mmHg; SBP variable, often non-significant at standard supplemental doses.

CRP and Oxidative-Stress Marker Reduction

In adults with metabolic disease, cinnamon reduces CRP and malondialdehyde (a lipid-peroxidation marker), reflecting an anti-inflammatory and antioxidant effect plausibly tied to proanthocyanidin and cinnamaldehyde activity. Jafari et al. (2025) reported SMD −0.78 for CRP and −0.76 for malondialdehyde. The clinical translation of these biomarker shifts to hard outcomes is not established.

Magnitude: CRP −0.5 to −1.5 mg/L at 1–3 g/day for 8–12 weeks in metabolic-disease populations.

Primary Dysmenorrhea Pain Reduction

Cinnamon at doses of 420–1500 mg three times daily during menses reduces the intensity and duration of primary dysmenorrhea (cyclic pelvic pain unrelated to pelvic pathology). The mechanism likely involves prostaglandin-pathway modulation. Xu et al. (2020) pooled three cinnamon vs. placebo RCTs and reported a weighted mean difference in pain intensity of 1.82 (visual analog scale points), with cinnamon also shortening pain duration by approximately 16 hours.

Magnitude: ~1.8-point reduction on 0–10 visual analog pain scale; pain duration reduced by approximately 16 hours per cycle.

Speculative 🟨

Neurodegeneration Slowing (Alzheimer’s, Parkinson’s)

Preclinical work suggests cinnamaldehyde, cinnamic acid, and proanthocyanidins interfere with tau aggregation, reduce beta-amyloid plaque burden, and protect dopaminergic neurons in animal models of Alzheimer’s and Parkinson’s disease. The hepatic metabolite sodium benzoate crosses the blood-brain barrier, providing a plausible CNS-delivery mechanism. No human RCTs have demonstrated cognitive or motor-disease benefit; the evidence is mechanistic and animal-model-based only.

Cancer-Risk Modulation

In vitro and rodent studies report that cinnamon extracts and cinnamaldehyde induce apoptosis in tumor cell lines and slow growth in xenograft models (breast, colon, melanoma). No human evidence currently links cinnamon supplementation to cancer-incidence or progression endpoints; the basis is mechanistic and preclinical only.

Antimicrobial and Oral-Health Effects

Cinnamaldehyde and eugenol exhibit broad antimicrobial activity in vitro against oral, gastrointestinal, and respiratory pathogens. Small short-duration trials of cinnamon-containing oral products report reduced plaque and gingival inflammation. The translation to systemic-health outcomes (gut-microbiome composition, infection risk) is unstudied in humans at supplemental doses.

Benefit-Modifying Factors

  • Baseline metabolic status: Effects on fasting glucose, HbA1c, HOMA-IR, and lipids are substantially larger in adults with T2DM, prediabetes, metabolic syndrome, or PCOS than in metabolically healthy adults — meta-analyses with mixed populations consistently show small or null effects, while T2DM-only meta-analyses show clear benefit.

  • Cinnamon species and form: Standardized extracts (e.g., aqueous extracts concentrating water-soluble polyphenols) and encapsulated whole-bark powders both produce metabolic effects, but trial-level evidence is most consistent for cassia and cassia-derived extracts at the doses studied; Ceylon-only trials are fewer. Substituting Ceylon at the same milligram dose has not been formally tested for equivalence in most outcomes.

  • Dose: Below approximately 1 g/day, glycemic and lipid effects are inconsistent; effects strengthen at 1.5–3 g/day. Body-composition effects appear most reliably at ≥2 g/day for ≥12 weeks. Doses above 6 g/day are not better-supported and increase coumarin exposure.

  • Duration: HbA1c and body-composition outcomes require ≥8–12 weeks; fasting glucose and acute postprandial effects appear within days to weeks.

  • Age: Body-composition benefits are larger in adults <50 years; glycemic benefits appear consistent across the adult age range.

  • Sex: PCOS-specific evidence (Heshmati 2021, Xiaomei 2024) is sex-specific by definition; broader metabolic effects appear similar across sexes in mixed-population meta-analyses, though most trials are sex-mixed without subgroup analyses.

  • Concurrent therapy: Patients on metformin or oral hypoglycemics show smaller incremental cinnamon effects (ceiling-related); patients diet-controlled or untreated typically show larger absolute changes.

  • Genetic polymorphisms: No pharmacogenomic predictors of cinnamon response are validated. CYP2A6 (a hepatic enzyme involved in coumarin 7-hydroxylation, the detoxifying first step) variants may influence individual susceptibility to coumarin-related liver effects but do not predict efficacy of cinnamon’s primary metabolic actions.

Potential Risks & Side Effects

A dedicated search across drug references (drugs.com, EMA monographs, BfR risk assessments) and primary-trial AE (adverse event) reporting informed the risks below.

High 🟥 🟥 🟥

Hepatotoxicity from Coumarin (Cassia Cinnamon)

Coumarin in cassia cinnamon (typical content 0.1–1% by weight, sometimes higher) is a documented hepatotoxin in sensitive individuals. The mechanism is metabolic activation by CYP2A6 to a hepatotoxic ortho-hydroxyphenylpropionaldehyde intermediate. The European Food Safety Authority’s TDI (tolerable daily intake) is 0.1 mg/kg body weight (~5–7 mg for a typical adult); a single teaspoon of cassia cinnamon (approximately 2.6 g) can contain 5–12 mg of coumarin, exceeding the TDI. Documented case reports of cassia-related hepatitis (elevated ALT (alanine aminotransferase, a liver enzyme), AST (aspartate aminotransferase, a liver enzyme), bilirubin) have appeared, with reversibility on cessation. Ceylon cinnamon (~0.004% coumarin) is essentially exempt from this risk at culinary or supplemental doses.

Magnitude: 1 tsp cassia cinnamon = 5–12 mg coumarin = 100–240% of EFSA TDI for a 70 kg adult.

Medium 🟥 🟥

Hypoglycemia in Combination with Diabetes Medications

Because cinnamon lowers fasting and postprandial glucose, co-administration with insulin, sulfonylureas (a class of insulin-secretion-stimulating drugs, e.g., glipizide, glyburide), or other hypoglycemic agents can produce additive hypoglycemia (low blood sugar). Reported events are mild-to-moderate and occur disproportionately at higher cinnamon doses (≥3 g/day) in patients with already-controlled glycemia. Patients with hypoglycemia-unawareness are at greater risk.

Magnitude: Glycemic-event risk increases proportionally to baseline hypoglycemic-drug intensity; not quantified per gram of cinnamon in trial data.

Heavy Metal and Coumarin Contamination Variability

Independent testing by ConsumerLab (2025/2026 review) identified meaningful coumarin in supplements labeled as Ceylon (suggesting cassia mislabeling), excess coumarin in one ground spice exceeding safety limits, and detectable lead in several products. Cinnamon — like other bark-derived spices — bioaccumulates soil heavy metals depending on growing region. The risk is product-specific rather than intrinsic to cinnamon as a substance.

Magnitude: Coumarin variation 100-fold between Ceylon and cassia; lead variation product-specific; ~25% of one independent test set was approved for quality.

Low 🟥

Gastrointestinal Discomfort

Mild dyspepsia (indigestion or upper-abdominal discomfort), nausea, heartburn, and bloating are reported in trial AE data at doses ≥3 g/day, particularly with cassia cinnamon and on an empty stomach. These effects are typically self-limiting and resolve with dose reduction or co-administration with food.

Magnitude: Affects approximately 5–10% of trial participants at ≥3 g/day; rare at ≤1.5 g/day.

Allergic Reactions and Mucosal Irritation

Contact dermatitis, oral mucosal irritation, and rare systemic IgE-mediated allergy (a fast-onset immune response involving immunoglobulin E) have been reported with cinnamon, primarily with concentrated cinnamon oil or the “cinnamon challenge” (oral aspiration of large quantities of dry powder). Cross-reactivity with balsam of Peru is documented in fragrance-allergic individuals.

Magnitude: Rare; isolated case reports.

Although coumarin (the natural compound in cassia) is structurally related to but distinct from the prescription anticoagulant warfarin, isolated reports describe increased INR (international normalized ratio, a measure of clotting time) in patients on warfarin who consumed large amounts of cassia. The clinical significance at culinary or modest supplement doses is uncertain; the concern is greatest at high cassia intakes combined with vitamin-K-antagonist therapy.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Renal Effects from High-Dose Coumarin

Animal studies suggest very high coumarin exposure can produce renal as well as hepatic toxicity, but human evidence at supplemental doses is absent. The basis is animal toxicology only, not human reports.

Drug Metabolism Interference via CYP Modulation

In vitro work suggests cinnamaldehyde and proanthocyanidins may modulate cytochrome P450 (a family of liver enzymes that metabolize most drugs) activity, including CYP3A4 (a major hepatic enzyme metabolizing roughly half of clinically used drugs) and CYP2A6, with theoretical implications for narrow-therapeutic-index drugs (warfarin, tacrolimus, certain anticonvulsants). Clinical-grade evidence is absent.

Risk-Modifying Factors

  • Cinnamon species: The single largest risk modifier. Cassia varieties carry virtually all of the coumarin-related hepatotoxic and bleeding risk; Ceylon (Cinnamomum verum) reduces this risk by approximately 100-fold at any given gram-dose.

  • Body weight: EFSA’s TDI is per-kilogram, so smaller adults and especially children exceed the threshold at lower absolute doses; the same teaspoon of cassia represents a higher proportional exposure for a 50 kg adult than a 90 kg adult.

  • Pre-existing liver disease: Patients with chronic hepatitis, cirrhosis, NAFLD (non-alcoholic fatty liver disease, accumulation of fat in the liver not caused by alcohol), or hepatotoxic-drug exposure (e.g., methotrexate, isoniazid) have lower hepatic reserve for coumarin metabolism — favoring Ceylon cinnamon and lower doses.

  • Concurrent diabetes therapy: Insulin and insulin-secretagogue (sulfonylurea, meglitinide) users carry greater hypoglycemia risk and may require glucose-monitoring intensification when adding cinnamon at ≥1.5 g/day.

  • Concurrent anticoagulation: Patients on warfarin or other vitamin-K antagonists should preferentially use Ceylon cinnamon and remain at culinary doses; therapeutic supplemental cassia at multi-gram doses is best avoided.

  • Pregnancy: High-dose cinnamon supplementation is not advised in pregnancy owing to traditional emmenagogue (substance that stimulates menstrual flow) use, theoretical uterine-stimulating effects of cinnamaldehyde, and no positive safety data; culinary use is considered safe.

  • Sex: Cinnamon-specific adverse-event profiles do not differ meaningfully between sexes in pooled trial data, but coumarin’s per-kilogram TDI means smaller-bodied adult women on average reach the threshold at lower absolute doses than larger adult men. Contact dermatitis and oral mucosal irritation reports show no clear male-female skew. Sex-specific pregnancy risks are addressed separately above.

  • Genetic polymorphisms: CYP2A6 poor-metabolizer variants reduce clearance of coumarin and theoretically increase hepatotoxicity risk, but routine genotyping is not clinically indicated.

  • Age: Older adults tend to have reduced hepatic reserve and more concurrent medications; coumarin and drug-interaction concerns scale accordingly.

  • Baseline biomarkers: Patients with already-elevated liver enzymes warrant Ceylon-only choices and lower cumulative doses.

Key Interactions & Contraindications

  • Antidiabetic medications (insulin, sulfonylureas — glipizide, glyburide, glimepiride; meglitinides — repaglinide, nateglinide; metformin; SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors, drugs that lower blood glucose by causing the kidneys to excrete glucose in urine) — empagliflozin, dapagliflozin; GLP-1 agonists (glucagon-like peptide-1 receptor agonists, drugs that mimic an incretin hormone to enhance insulin release and slow gastric emptying) — semaglutide, liraglutide): Caution; monitor. Additive blood-glucose lowering can produce symptomatic hypoglycemia; consider glucose monitoring intensification when starting cinnamon at ≥1.5 g/day and discuss dose adjustment with the prescriber.

  • Vitamin-K antagonists (warfarin, acenocoumarol, phenprocoumon): Caution. Cassia cinnamon at multi-gram doses may modestly elevate INR; prefer Ceylon cinnamon and limit to culinary doses, or monitor INR if therapeutic doses are pursued.

  • Over-the-counter analgesics and NSAIDs (acetaminophen, aspirin, ibuprofen, naproxen): Caution. High-dose acetaminophen plus cassia cinnamon adds to hepatic load via coumarin; concurrent NSAIDs/aspirin and high-dose cassia carry a theoretical additive bleeding risk via coumarin’s structural relationship to anticoagulants. Limit to culinary doses or prefer Ceylon when these OTC agents are used regularly.

  • Hepatotoxic drugs (acetaminophen at high doses, methotrexate, isoniazid, statins, valproate, amiodarone): Caution. Concurrent high-dose cassia cinnamon adds to hepatic load via coumarin; prefer Ceylon and the lowest effective dose.

  • Other glucose-lowering supplements (berberine, gymnema, fenugreek, alpha-lipoic acid, chromium, bitter melon): Caution; additive effects. Stacking multiple glucose-lowering agents amplifies hypoglycemia risk in medicated diabetic patients; combinations are common in nutraceutical formulas (e.g., CinSulin).

  • Anticoagulant or antiplatelet supplements (high-dose fish oil, garlic extract, Ginkgo biloba, vitamin E, curcumin): Caution. Theoretical additive bleeding risk with cassia cinnamon; effect at culinary or modest supplemental doses is small.

  • Hepatically metabolized narrow-therapeutic-index drugs (cyclosporine, tacrolimus, certain anticonvulsants): Monitor. In-vitro CYP modulation by cinnamon constituents has uncertain clinical relevance; clinical monitoring of drug levels is appropriate when starting therapeutic-dose cinnamon.

  • Alcohol: Caution. Heavy regular alcohol intake plus high-dose cassia may compound hepatic stress.

Populations who should avoid or restrict cinnamon:

  • Patients with active hepatitis or transaminases >3× ULN (upper limit of normal).

  • Patients with NAFLD with significant fibrosis (e.g., NAFLD with FIB-4 (Fibrosis-4 Index, a non-invasive score combining age, AST, ALT, and platelet count to estimate liver fibrosis severity) >2.67) — favor Ceylon-only and low doses.

  • Pregnant individuals (avoid supplemental doses; culinary use acceptable).

  • Children under 12 (the EFSA TDI is more easily exceeded; supplemental dosing not indicated).

  • Patients on warfarin with INR variability — avoid therapeutic-dose cassia.

  • Patients with documented cinnamon or balsam-of-Peru allergy.

Risk Mitigation Strategies

  • Use Ceylon (Cinnamomum verum) for daily supplemental use: This single change reduces coumarin exposure by approximately 100-fold (from ~1% in cassia to ~0.004% in Ceylon) and eliminates the bulk of hepatotoxicity and bleeding-related concern at any given dose.

  • Cap daily intake at 3 g/day for cassia, 6 g/day for Ceylon (typical adult): Cassia at ≥3 g/day approaches or exceeds the EFSA coumarin TDI; Ceylon’s much lower coumarin allows higher gram doses without exceeding the TDI.

  • Verify product source via third-party testing: ConsumerLab’s 2025/2026 review found two supplements mislabeled (cassia sold as Ceylon) and detectable coumarin in unexpected places. Choose USP-verified, NSF-certified, or independently tested products to address coumarin and lead variability.

  • Schedule baseline and follow-up liver-enzyme testing: Check ALT, AST, alkaline phosphatase, and bilirubin at baseline, 8–12 weeks, then annually for adults using ≥3 g/day cassia (and consider similar monitoring at any sustained therapeutic dose) — addresses asymptomatic hepatocellular injury risk.

  • Take with meals: Co-administering cinnamon with the meal whose postprandial glucose excursion is highest (typically dinner, in many adults) maximizes the postprandial-blunting mechanism and minimizes gastrointestinal irritation.

  • For diabetic patients on hypoglycemic agents — intensify glucose monitoring during the first 2 weeks: Self-monitored or continuous-glucose-monitoring data inform whether antidiabetic dose reduction is warranted, mitigating hypoglycemia.

  • Stop preoperatively: Discontinue therapeutic-dose cinnamon (especially cassia) at least one week before scheduled surgery to avoid potential additive bleeding effects with anesthesia and perioperative anticoagulation.

  • Avoid concentrated cinnamon oil internally: Cinnamon essential oil contains 10–100× the cinnamaldehyde concentration of bark powder; oral use can produce mucosal burns and severe gastrointestinal irritation.

Therapeutic Protocol

A typical evidence-aligned protocol used by integrative practitioners and longevity-oriented clinicians follows; clinician Brad Stanfield (drstanfield.com) and the functional-medicine writer Chris Kresser (chriskresser.com) are representative voices for the Ceylon whole-bark approach, and Life Extension’s CinSulin protocol popularized the standardized aqueous extract approach in U.S. supplement practice.

  • Form: Encapsulated Ceylon (Cinnamomum verum) bark powder — preferred for sustained daily use due to coumarin profile. Standardized aqueous cassia extracts (e.g., CinSulin/Cinnulin PF, the formulation popularized by Life Extension) concentrate the water-soluble polyphenols while removing the lipid-soluble coumarin and are an acceptable alternative when sourced and tested.

  • Dose: 1–3 g/day Ceylon bark powder (approximately 1/2 to 1.2 tsp) for general metabolic support; up to 6 g/day Ceylon for adults targeting clear glycemic outcomes. Standardized cassia aqueous extract: 250–500 mg twice daily.

  • Timing — best time of day: With meals (preferably the largest carbohydrate-containing meal). Splitting the dose to capture postprandial glucose spikes at multiple meals (e.g., 1 g with breakfast and 1 g with dinner) is consistent with the short plasma half-life of cinnamaldehyde.

  • Half-life: Cinnamaldehyde and its primary metabolites (cinnamic acid, hippuric acid) have plasma half-lives of approximately 1–4 hours; sustained daily dosing is required for biomarker effects.

  • Single vs split dose: Split dosing (twice daily with meals) is preferred for postprandial-glucose blunting; once-daily dosing is acceptable for general metabolic support.

  • Duration to assess effect: Reassess fasting glucose at 4–6 weeks, HbA1c and lipid panel at 12 weeks, body composition at 12–24 weeks.

  • Sex-based differences: PCOS-specific evidence supports cinnamon for insulin resistance in women; no other sex-based dosing adjustments are established.

  • Age-related considerations: Older adults with reduced hepatic reserve, polypharmacy, or fragile glycemic control should start lower (500 mg–1 g/day Ceylon) and titrate.

  • Genetic polymorphisms: CYP2A6 poor-metabolizer variants are not routinely tested but theoretically warrant Ceylon-only choices and lower doses if known.

  • Baseline biomarker considerations: Adults with elevated baseline LDL-c, triglycerides, fasting glucose, HbA1c, or HOMA-IR have larger expected effect sizes; metabolically healthy adults should not expect meaningful shifts in these biomarkers.

  • Pre-existing condition considerations: Patients with T2DM on insulin or sulfonylureas should coordinate with their prescriber and consider glucose-monitoring intensification; patients with NAFLD or elevated liver enzymes should use Ceylon only.

  • Stacking partners: Common combinations include cinnamon + chromium picolinate, cinnamon + berberine, and cinnamon + alpha-lipoic acid for glycemic support; cinnamon + bergamot and cinnamon + red yeast rice for lipid support. Hypoglycemia and hepatotoxicity risks are additive.

Discontinuation & Cycling

  • Lifelong vs short-term: Cinnamon is intended for chronic, ongoing supplementation in metabolically motivated use; trial durations are typically 8–24 weeks but the underlying biomarker effects appear sustained as long as dosing continues.

  • Withdrawal effects: None documented. Glycemic and lipid biomarkers gradually return toward baseline over weeks-to-months after cessation.

  • Tapering protocol: Not required.

  • Cycling for efficacy: No evidence supports cycling for tolerance or efficacy; the plasma-half-life and biomarker pharmacodynamics do not suggest tachyphylaxis. Some clinicians cycle (e.g., 12 weeks on, 4 weeks off) to allow periodic biomarker reassessment without confounding by concurrent supplementation rather than to maintain efficacy.

Sourcing and Quality

  • Species verification: Choose products that explicitly identify the species as Cinnamomum verum (Ceylon) and ideally show certificate-of-analysis confirmation. Generic “cinnamon” labeling without species identification is presumptively cassia.

  • Coumarin testing: Reputable Ceylon products show <50 mg/kg coumarin on COA (certificate of analysis); cassia products typically show 1,000–10,000 mg/kg. Mislabeling exists — independent testing has identified Ceylon-labeled products with cassia-range coumarin.

  • Heavy metal testing: Cinnamon, like other bark spices, can bioaccumulate lead and cadmium; choose products with documented heavy-metal limits (USP <232>, NSF, or similar third-party testing).

  • Standardization: For aqueous-extract products, look for proanthocyanidin standardization (e.g., Cinnulin PF® specifies a Type-A polymer fraction) and a defined daily dose tied to clinical-trial precedent.

  • Reputable brands: Brands that have appeared in ConsumerLab reviews and met quality criteria include Ceylon-specific options from Whole Foods 365, Anthony’s, Frontier Co-Op, Simply Organic (spices); and CinSulin (Life Extension) and Swanson (supplements). Brand-by-brand performance changes — current independent test data should be consulted.

  • Avoid concentrated essential oil for internal use: Cinnamon bark essential oil is hazardous orally and topically without significant dilution; therapeutic protocols should not rely on it.

Practical Considerations

  • Time to effect: Acute postprandial glucose blunting is detectable within hours of a single dose; fasting-glucose changes at 2–4 weeks; HbA1c, lipid, and body-composition effects at 8–12 weeks.

  • Common pitfalls: Choosing cassia for daily supplemental use (coumarin overload), dosing too low (<1 g/day produces inconsistent effects), discontinuing too early (<8 weeks misses HbA1c-detectable change), assuming “cinnamon is cinnamon” and ignoring species, taking very high doses (>6 g/day) without species verification, and using cinnamon as a substitute for established diabetes therapy rather than an adjunct.

  • Regulatory status: Cinnamon is regulated as a food and dietary supplement (GRAS — generally recognized as safe — for food use in the United States); not FDA-approved for any disease indication. EFSA has set a coumarin TDI but does not regulate cinnamon as a medicine.

  • Cost and accessibility: Inexpensive and widely available. Quality Ceylon supplements typically cost $10–20/month at therapeutic doses; ground Ceylon spice is widely available at $5–15 per 4-oz container. The cost differential between Ceylon and cassia is modest at supplemental doses.

Interaction with Foundational Habits

  • Sleep: Direct effect minimal. Indirect: improved postprandial glucose stability may modestly reduce nocturnal cortisol/adrenaline excursions in patients with reactive hypoglycemia or unstable evening glycemia. No evidence of sleep disruption at supplemental doses; cinnamon is sometimes consumed with chamomile, lemon balm, or other evening teas without apparent interference.

  • Nutrition: Direct, potentiating. Cinnamon’s strongest measurable effects appear when combined with carbohydrate-containing meals — postprandial-glucose blunting is most relevant in adults consuming mixed-macronutrient diets including starches and added sugars. The effect is partly redundant with low-glycemic-load diets (e.g., Mediterranean, low-carb), where postprandial excursions are already smaller. Stacks well with protein-leveraged meals.

  • Exercise: Indirect, potentiating. Cinnamon’s insulin-sensitization complements exercise-induced GLUT4 (glucose transporter type 4) translocation, with theoretical synergy for glycemic control. No human studies have evaluated cinnamon timing relative to workouts; pre-workout dosing is not necessary.

  • Stress management: Indirect. Chronic stress elevates cortisol, blood glucose, and visceral fat; cinnamon may partially offset the metabolic component but does not address the upstream stress driver. The intervention is a downstream tool, not a substitute for stress management.

Monitoring Protocol & Defining Success

A practical monitoring plan starts with baseline labs and proceeds with periodic reassessment to track both efficacy and safety, particularly for patients using ≥3 g/day or cassia.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–85 mg/dL Primary efficacy outcome Conventional reference range extends to 99 mg/dL; functional optimum is tighter. Fasting required (8–12 h).
HbA1c <5.3% Integrated 8–12 week glycemic exposure Conventional reference <5.7% (normal) / 5.7–6.4% (prediabetes); functional optimum is tighter. No fasting needed.
Fasting insulin 2–6 µIU/mL Insulin resistance indicator Conventional reference often extends to 24 µIU/mL; functional optimum is much lower. Fasting required.
HOMA-IR <1.5 Calculated insulin resistance Calculated as (fasting glucose × fasting insulin) / 405; higher values indicate greater insulin resistance.
LDL-c Patient-individualized (<100 mg/dL conventional; lower for elevated CV risk) Lipid efficacy outcome Standard fasting lipid panel; ApoB is a complementary marker if available.
Triglycerides <80 mg/dL Lipid efficacy outcome and metabolic-syndrome marker Fasting required (12 h); strongly diet- and alcohol-influenced.
HDL-c >50 mg/dL (women); >40 mg/dL (men) Lipid efficacy outcome Direction of cinnamon effect is small but positive in meta-analysis.
ALT <19 U/L (women); <30 U/L (men) Hepatotoxicity surveillance (especially cassia) Conventional reference range extends higher (~35–55 U/L); functional optimum is tighter. Consider testing at baseline, 8–12 weeks, then annually for therapeutic-dose users.
AST <25 U/L Hepatotoxicity surveillance Conventional reference range up to ~40 U/L; functional optimum is tighter. Pair with ALT.
hsCRP <1.0 mg/L Inflammation outcome Avoid testing during acute illness; can transiently spike with infection.
Body composition (waist circumference, weight) Waist <35 in (women), <40 in (men) Body-composition efficacy outcome Measure at navel, exhalation.

Baseline testing is typically performed before initiating cinnamon at therapeutic doses (≥1.5 g/day) — particularly for adults with metabolic disease, polypharmacy, or hepatic risk factors — to capture the starting point against which improvement is measured.

Ongoing monitoring is typically performed at 4–6 weeks for fasting glucose response, at 12 weeks for HbA1c and lipid panel, then every 6–12 months for sustained users. Liver enzymes warrant baseline, 8–12 weeks, and annual reassessment in cassia users at ≥3 g/day.

Qualitative markers to track:

  • Postprandial energy stability (fewer crashes, less afternoon fatigue)

  • Reduction in carbohydrate cravings

  • Subjective digestive comfort with cinnamon-containing meals

  • Self-monitored or continuous-glucose-monitor data showing blunted postprandial spikes

  • Absence of right-upper-quadrant discomfort, jaundice, or unexplained fatigue (potential hepatic warning signs)

Emerging Research

  • Major ongoing trials: A handful of registered cinnamon-containing trials are advancing the human-evidence base. NCT06700915 (n=80, 24 weeks) is a triple-blind RCT of a berberine-plus-cinnamon nutraceutical (Diaberine) for blood-sugar regulation in adults with metabolic dysfunction. NCT06515652 (n=200, 90 days) compares an allopathic regimen against a polyherbal formulation containing Cinnamomum verum in metabolic syndrome. NCT06889961 (n=50, 6 months) evaluates a cinnamon-containing mixed-spice capsule for memory and cognitive function in adults aged 50–80 with mild age-related cognitive decline. NCT07390266 (n=30) tests an Origin Satiety Complex including cinnamon for self-reported hunger and satiety.

  • Larger and longer cardiometabolic RCTs: The 2025 umbrella review (Gou et al.) and the 2025 GRADE-assessed dose-response meta-analysis (Jafari et al.) explicitly call for trials beyond the typical 8–12 week duration with hard cardiovascular endpoints rather than biomarker surrogates — a gap that, if filled, could either confirm or restrict the current biomarker-based case.

  • Neurodegeneration translation: Mechanistic preclinical work continues on cinnamaldehyde and proanthocyanidins as tau-aggregation inhibitors and Parkinson’s-relevant neuroprotective agents. The first translation is a large mixed-spice cognition trial (NCT06889961); cinnamon-only neurodegeneration RCTs in humans remain awaited.

  • Standardized-extract characterization: Trials using aqueous extracts (Cinnulin PF, CinSulin) report effects at much lower milligram doses than whole-bark powder, raising the question of which fractions drive the metabolic effects and whether formulation can decouple efficacy from coumarin exposure. Yu et al. 2023 (Nutrients) provided a dose-response analysis suggesting non-linear relationships at moderate doses.

  • Cancer and microbiome evaluation: Preclinical signal in colon and breast cancer cell lines and animal models supports human follow-up; no large human trials are registered. Microbiome work is similarly preliminary.

  • Reaffirmation or restriction of glycemic claims: Notably, Krittanawong et al. 2022 (American Journal of Medicine) reached a null conclusion on cinnamon’s effect on HbA1c, LDL-c, and HDL-c — citing trial-quality concerns. The dispute is unresolved; whether subsequent larger high-quality trials confirm the meta-analytic positive signal or the more restrictive American Journal of Medicine view is the central open question.

Conclusion

Cinnamon is one of the most extensively studied spices in modern human metabolic research, and the combined evidence base of dozens of randomized trials and multiple meta-analyses points to a real, modest, biomarker-level signal: lower fasting glucose, somewhat lower long-term blood-sugar averages, and improved blood-lipid and inflammation profiles in adults with type 2 diabetes, prediabetes, hormonal-cycle insulin resistance, or metabolic syndrome. Body weight and waist circumference also fall slightly at higher daily intakes over twelve weeks or more. The effects are larger in metabolically unwell adults than in healthy adults, and they appear to be additive to — not a substitute for — established lifestyle and pharmacological care.

The dominant safety distinction is between Ceylon and cassia varieties: cassia is the dominant supply but contains roughly a hundredfold more coumarin, which can stress the liver at routine supplemental doses. Choosing Ceylon for daily therapeutic use neutralizes most of this concern. Hypoglycemia in patients on diabetes medications, product-quality variability, and bleeding-risk considerations on blood-thinner therapy remain practical issues to manage.

The evidence base, while extensive, has notable heterogeneity and a major dissenting meta-analysis. The current biomarker-level signal is robust enough to inform practice for the longevity-oriented adult; effects on direct lifespan and healthspan outcomes lie outside the scope of the present human evidence.

Top - Benefits - Risks - Protocol